文献速递免疫规划

野生型与lpxL/lpxM突变体灭活疫苗对比:针对禽致病性大肠杆菌O1、O2和O78攻毒的安全性与效力

Comparison of the safety and efficacy of the wild-type and lpxL/lpxM mutant inactivated vaccine against the avian pathogenic Escherichia coli O1, O2, and O78 challenge.
PubMed 文献 · Vaccine · 2024-03-18

研究以白来航鸡评价针对禽致病性大肠杆菌O1、O2、O78的lpxL/lpxM突变体灭活疫苗与野生型灭活疫苗的安全性及效力。突变疫苗组免疫后食欲恢复更快、注射部位结节消失更早,免疫后14天野生型疫苗组肝、肺和注射部位仍有病变而突变疫苗组无病变。同剂量攻毒时两组抗体水平、死亡率和病变评分无显著差异,突变疫苗单剂或超剂量对肉鸡无不良影响并能保护攻毒。

要点

  • 突变疫苗组免疫后食欲恢复更快、注射部位结节消失更早。
  • 免疫后14天野生型疫苗组肝、肺和注射部位仍有病变,突变疫苗组无病变。
  • 同剂量攻毒时两组抗体水平、死亡率和病变评分无显著差异。

核心结论

  • 与野生型疫苗相比,lpxL/lpxM突变体多价灭活疫苗是抗APEC O1、O2和O78感染的竞争性候选疫苗。

研究设计与样本

  • 研究以白来航鸡评价lpxL/lpxM突变株及O1、O2、O78野生株灭活疫苗(分别称突变疫苗和野生型疫苗)的安全性与效力。
  • 研究在肉鸡中评价了突变疫苗单剂或超剂量的安全性及其一剂效力。

主要发现

  • 鸡免疫突变疫苗后食欲恢复更快、注射部位结节消失更早。
  • 免疫后14天野生型疫苗组肝、肺和注射部位仍有病变,突变疫苗组无病变。
  • 同剂量攻毒时,突变疫苗组与野生型疫苗组在攻毒日抗体水平、死亡率和病变评分上无显著差异。
  • 突变疫苗单剂或超剂量对肉鸡无不良影响,并保护其抵抗APEC O1、O2或O78株攻毒。

关键数值与推荐

  • 去除lpxL和lpxM基因使野生APEC菌株内毒素水平下降八倍。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Avian pathogenic Escherichia coli (APEC) is primarily responsible for causing septicemia, pneumonitis, peritonitis, swollen head syndrome, and salpingitis in poultry, leading to significant losses in the poultry sector, particularly within the broiler industry. The removal of the lpxL and lpxM genes led to an eightfold decrease in the endotoxin levels of wild APEC strains. In this study, mutant strains of lpxL/lpxM and their O1, O2, and O78 wild-type strains were developed for an inactivated vaccine (referred to as the mutant vaccine and the wild-type vaccine, respectively), and the safety and effectiveness of these two prototype vaccines were assessed in white Leghorn chickens. Findings indicated that chickens immunized with the mutant vaccine showed a return of appetite sooner post-immunization and experienced earlier disappearance of nodules at the injection site compared to those immunized with the wild-type vaccine. Pathological examinations revealed that lesions were still present in the liver, lung, and injection site in chickens vaccinated with the wild-type vaccine 14 days post-vaccination (dpv), whereas no lesions were found in chickens vaccinated with the mutant vaccine at 14 dpv. There were no significant differences in antibody levels on the challenge day or in mortality or lesion scores between challenged birds immunized with either the mutant vaccine or the wild-type vaccine at the same dose. In this study, the safety of a single dose or overdose of the mutant vaccine and its efficacy at one dose were evaluated in broilers, and the results showed that the mutant vaccine had no adverse effects on or protected vaccinated broilers from challenge with the APEC O1, O2, or O78 strains. These results demonstrated that the mutant polyvalent inactivated vaccine is a competitive candidate against APEC O1, O2, and O78 infection compared to the wild-type vaccine.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Wu J, Jiang L, Shao Q, et al. Comparison of the safety and efficacy of the wild-type and lpxL/lpxM mutant inactivated vaccine against the avian pathogenic Escherichia coli O1, O2, and O78 challenge. Vaccine. 2024. PMID: 38503663. doi:10.1016/j.vaccine.2024.03.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。